REGENXBIO Q3 net loss $59.6M; cash $278.6M; RGX-202 pivotal trial initiation expected this month

REGENXBIO Inc.

2024-Q3 EPS reported -$3.59 revenue$62,114,000

Net loss of $59.6M ($1.17 EPS) vs $61.9M ($1.41 EPS) in Q3 2023.
Revenue $24.2M, down from $28.9M, driven by lower Zolgensma royalties ($23.9M vs $28.4M).
Cash, cash equivalents and marketable securities $278.6M as of Sep 30, 2024.
RGX-202 pivotal trial initiation and first functional data expected November 2024.
BLA submission for RGX-121 (MPS II) initiated, expected completion Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.